by mikewp | Feb 10, 2016 | Blog, Drug Development Consulting, Gilbert “Chip” W. Carnathan, Regulatory Affairs
February 10, 2016 | Chip Carnathan, PhD, RAC, Director Regulatory Affairs | Regulatory Affairs, Drug Development Consulting Yeah, yeah, we know. The general public considers biosimilars to be “generic” versions of approved biological products. The FDA has gone to...
by mikewp | Aug 20, 2015 | Blog, Mark Cierpial, Regulatory Affairs
August 20, 2015 | Mark Cierpial, PhD, RAC, Chief Executive Officer | Regulatory Affairs We’ve all seen or heard them – either in popular magazines and newspapers or on television and radio – advertisements directed to us, the consumers of prescription...
